Surgical therapy for hepatocellular carcinoma patients with biliary tract tumor thrombus
10.3760/cma.j.cn113855-20210724-00451
- VernacularTitle:原发性肝细胞癌合并胆道癌栓的手术疗效分析
- Author:
Yao SHEN
1
;
Jingbo HUANG
;
Hui ZHANG
;
Yahui LIU
;
Xiaohui DUAN
;
Xianhai MAO
Author Information
1. 湖南师范大学附属第一医院（湖南省人民医院）肝胆胰外科，长沙 410005
- Keywords:
Carcinoma,hepatocellular;
Biliary tract;
Tumor thrombus
- From:
Chinese Journal of General Surgery
2022;37(5):334-338
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate surgical therapy for patients of hepatocellular carcinoma(HCC) with bile duct tumor thrombi(BDTT).Methods:A retrospective analysis was made on 66 patients with HCC and BDTT undergoing surgical treatment at the First Affiliated Hospital of Hunan Normal University from Jan 2011 to Dec 2016.Results:The overall median survival time of the patients was 31 months. The 1, 3, and 5-year survival rates were 87.9%, 45.5%, and 13.6%, respectively. Univariate analysis showed hepatitis B virus, liver cirrhosis and history of drinking, AFP≥200 ng/ml, tumor resection combined with biliary incision to remove tumor thrombus, tumor undifferentiated/poorly differentiated, tumor diameter ≥50 mm, AJCC 8th stage Ⅲ/Ⅳ and number of lesions ≥ 2 were risk factors for postoperative survival (all P<0.05). Multivariate analysis showed that drinking history, undifferentiated/poorly differentiated tumor, tumor diameter ≥50 mm, and AJCC 8th Ⅲ/Ⅳ stage were independent risk factors (all P<0.05). Conclusion:Surgical resection of HCC combined with BDTT can achieve a satisfactory survival and prognosis.
